Giménez Carabaza, N., Martínez Trillos, A., Montraveta, A., López-Guerra, M., Rosich, L., Nadeu Prat, F., . . . Villamor i Casas, N. (2019). Mutations in RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia.
Citación estilo ChicagoGiménez Carabaza, Neus, et al. Mutations in RAS-BRAF-MAPK-ERK Pathway Define a Specific Subgroup of Patients With Adverse Clinical Features and Provide New Therapeutic Options in Chronic Lymphocytic Leukemia. 2019.
Cita MLAGiménez Carabaza, Neus, et al. Mutations in RAS-BRAF-MAPK-ERK Pathway Define a Specific Subgroup of Patients With Adverse Clinical Features and Provide New Therapeutic Options in Chronic Lymphocytic Leukemia. 2019.